NASDAQ: TSBX - Turnstone Biologics Corp. Common Stock

半年間の収益性: -82.73%

プロモーションスケジュール Turnstone Biologics Corp. Common Stock

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors.

さらに詳しく
The company was founded in 2014 and is based in LA Jolla, California.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

EBITDA 0.0344
EV/EBITDA -3.51
IPO date 2023-07-21
ISIN US90042W1009
Industry Biotechnology
P/BV 0.2983
P/S 1.52
Sector Health Care
Валюта usd
Валюта отчета usd
Выручка 0.1013
Сайт https://turnstonebio.com
Цена ао 2.68
Число акций ао 0.01156 млрд
1日あたりの価格変動: 0% (0.4526)
週ごとの価格変動: -4.19% (0.4724)
月ごとの料金変更: -31.32% (0.659)
3ヶ月間の価格変動: -80.9% (2.37)
半年間の価格変動: -82.73% (2.62)
年間の価格変動: -79.7% (2.23)
3年間の価格推移: 0% (0.4526)
5年間の価格推移: 0% (0.4526)
10年間の価格推移: 0% (0.4526)
年初からの価格変動: -82.25% (2.55)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 1.78 8
P/BV 0.3481 10
P/E 0 0
EV/EBITDA -0.3514 0
合計: 6

効率

名前 意味 学年
ROA, % -48.93 0
ROE, % -55.95 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.0572 10
合計: 10

成長の衝動

名前 意味 学年
収益性 Revenue, % -80.94 0
収益性 Ebitda, % -263.47 0
収益性 EPS, % -418.26 0
合計: 1
さらに詳しく

機関 音量 共有, %
Orbimed Advisors LLC. 3099265 13.42
FMR, LLC 2546661 11.02
Bank of America Corporation 914058 3.96
Point72 Asset Management, L.P. 833333 3.61
Eventide Asset Management LLC 708317 3.07
Citadel Advisors Llc 688468 2.98
PFM Health Sciences, LP 633313 2.74
72 Investment Holdings, LLC 549981 2.38
Sectoral Asset Management, Inc. 517648 2.24
Blackrock Inc. 301925 1.31

ETF 共有, % 年間の利益率, % 配当金, %
iShares Micro-Cap ETF 0.00268 11.903735012508 1.54048

スーパーバイザー 役職 支払い 生年
Dr. Sammy J. Farah M.B.A., Ph.D. President, CEO & Director 678.51k 1973 (51 年)
Dr. Venkat Ramanan Ph.D. Chief Financial Officer 346.13k 1970 (54 年)
Dr. Michael F. Burgess M.D., MBChB, Ph.D. Interim Chief Medical Officer & Executive Director 212.69k 1963 (61 年)
Ms. Saryah Azmat Chief Business Officer 479.73k 1990 (34 年)
Dr. Vijay Chiruvolu M.B.A., Ph.D. Interim Chief Technology Officer N/A 1962 (62 年)
Dr. David Stojdl Ph.D. Senior Vice President of Research & Discovery
Dr. Ines Verdon M.D. Senior Vice President of Clinical Development

住所: United States, LA Jolla. CA, 9310 Athena Circle - Googleマップで開く, Yandexマップを開く
Webサイト: https://turnstonebio.com